Celltrion (068270.KS) Financial Analysis & Valuation | Quarter Chart
Celltrion (068270.KS)
068270.KSPrice: $130.68
Fair Value: 🔒
🔒score
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes ... more
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on protein... more
Description
Shares
| Market Cap | $28.54B | Exchange | KSC |
| Sector | Healthcare | Industry | Biotechnology |
| Country | KR | CEO | Woo-Sung Kee |
| IPO Date | 2005-07-19 | CAGR | 0.27% |
| Employees | 2,391 | Website | www.celltrion.com |
| Div. Yield | 0.38% | Payout Ratio | 0.12% |
| Buy Back Yield | 1.57% | Total Yield | 1.95% |
068270.KS chart loading...
Fundamentals
Technicals
| Enterprise Value | $48609.18B | P/E Ratio | — |
| Forward P/E | 26.33 | PEG Ratio | — |
| P/S Ratio | 9.72 | P/B Ratio | 2.63 |
| P/CF Ratio | 62.52 | P/FCF Ratio | 85.4 |
| EPS | $2.78 | EPS Growth 1Y | 143.76% |
| EPS Growth 3Y | 38.35% | EPS Growth 5Y | 37.69% |
| Revenue Growth 1Y | 21.94% | Gross Margin | 0.6% |
| Operating Margin | 0.3% | Profit Margin | 0.28% |
| ROE | 0.07% | ROA | 0.05% |
| ROCE | 0.07% | Current Ratio | 1.39 |
| Quick Ratio | 0.8 | Cash Ratio | 0.27 |
| Debt/Equity | 0.22 | Interest Coverage | 15.69 |
| Altman Z Score | 5.68 | Piotroski Score | 5 |